Recent late-stage oncology momentum spans clinical efficacy signals and regulatory movement: Sellas’ AML vaccine reported a 41% death-risk reduction, while GSK’s neladalkib secured accelerated approval for lung cancer following the Nuvalent acquisition. Together, the updates indicate continued oncology investment in both immune-based and targeted drug modalities. For biotech leaders, the combination of large AI/venture financing and fast-moving oncology regulatory outcomes suggests that product de-risking—through Phase 3 readouts or accelerated pathway approvals—remains the clearest path to capital attraction and pipeline confidence.